Draw
|
Currency :
Structure Search
AG007KIV
139481-59-7 | Candesartan
AG007KIV
SDS
COA
Add to Cart
Request For Quotation
- mg
- g
- kg
- ml
- L
无数据
无数据
- mg
- g
- kg
- ml
- L
无数据
| CAS Number | 139481-59-7 |
| Catalog Number | AG007KIV(AGN-PC-0POFHL) |
| Chemical Name | Candesartan |
| EC Number | 604-138-8 |
| IUPAC Name | 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid |
| InChI | InChI=1S/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29) |
| InChI Key | HTQMVQVXFRQIKW-UHFFFAOYSA-N |
| MDL Number | MFCD00864463 |
| Molecular Formula | C24H20N6O3 |
| Molecular Weight | 440.4540 |
| NSC Number | 759858 |
| SMILES | C(n1c2c(nc1OCC)cccc2C(=O)O)c1ccc(cc1)c1c(cccc1)c1[nH]nnn1 |
| UNII | S8Q36MD2XX |
| Synonyms | 2-ethoxy-7-carboxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole,
candesartan,
CV 11974,
CV-11974,
CV11974,
candesartan,
139481-59-7,
Blopress,
CV-11974,
Ratacand,
1-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylic acid,
CV 11974,
UNII-S8Q36MD2XX,
2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid,
CHEMBL1016,
S8Q36MD2XX,
2-Ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid,
CHEBI:3347,
C24H20N6O3,
2-ethoxy-3-[[4-[2-(1h-tetrazol-5-yl)phenyl]phenyl]methyl]-3h-benzoimidazole-4-carboxylic acid,
NCGC00167474-01,
AK-57139,
DSSTox_CID_2725,
DSSTox_RID_75453,
DSSTox_GSID_22725,
1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,
Candesartan [BAN],
[3H]candesartan,
2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid,
2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid,
1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylic acid,
2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid,
2-ethoxy-1-({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl)-1H-benzimidazole-7-carboxylic acid,
CAS-139481-59-7,
SR-05000001447,
Candesartan (USAN/INN),
Candesartan [USAN:INN],
CV11974,
cilexitil,
Candesartan [USAN:INN:BAN],
HSDB 7520,
2-ethoxy-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid,
2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4-benzimidazolecarboxylic acid,
2-ethoxy-1-[[2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]-1h-benzimidazole-7-carboxylic acid,
2-ethoxy-1-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-benzimidazole-7-carboxylic acid,
2-ethoxy-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid,
Candesartan(Atacand),
candesartan (Atacand),
KS-5003,
Candesartan - Atacand,
AC1L1DWT,
TCV-116 (prodrug),
2-ethoxy-7-carboxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole,
EC 604-138-8,
SCHEMBL3938,
GTPL587,
MLS003915631,
MLS004774041,
BIDD:GT0350,
GTPL6907,
DTXSID0022725,
CTK8E8165,
HTQMVQVXFRQIKW-UHFFFAOYSA-N,
BCPP000302,
HMS2089M22,
HMS3651C13,
HMS3715F13,
Pharmakon1600-01502288,
ACT02607,
BCP01137,
EBD40593,
HY-B0205,
KS-000001UX,
ZINC3782818,
Tox21_112478,
AC-203,
AN-839,
BDBM50240609,
CC0016,
MFCD00864463,
NSC759858,
s1578,
AKOS015888154,
AKOS025117340,
Tox21_112478_1,
AB07470,
AM84369,
API0001828,
AT-3243,
BCP9000479,
CCG-213059,
CS-2146,
DB13919,
NSC-759858,
RTR-005177,
NCGC00167474-02,
NCGC00167474-04,
NCGC00167474-06,
2-Ethoxy-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl] methyl]-3H-benzoimidazole-4-carboxylic acid,
BC205774,
BR-57139,
candesartan ( for candesartan cilexetil ),
LS-32740,
SC-15284,
SMR002203608,
SMR003500711,
AB0011997,
AX8018243,
ST2414902,
TL8000897,
4CH-015556,
C-266,
candesartan[candesartancilexetilintermediates],
FT-0083585,
FT-0602912,
SW199612-2,
C07468,
D00522,
J10263,
S-2839,
AB01275447-01,
AB01275447_02,
AB01275447_03,
481C597,
A807545,
A808309,
L000156,
I01-0374,
J-007281,
SR-05000001447-1,
SR-05000001447-2,
SR-05000001447-5,
2-Ethoxy-1-[[2'-(1 H-tetrazol-5-yl)biphenyl-4-yl]methyl]-benzimidazole-7-carboxylic acid,
2-Ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-benzimidazole-7-carboxylic acid,
2-Ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic Acid,
2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4ethyl]}-1H-benzimidazole-7-carboxylic acid,
2-Ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid.,
2-Ethoxy-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzimidazole-4-carboxylic acid,
1-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylic ac,
1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylic acid,
2-Ethoxy-1-((2-(1H-tetrazole-5-yl)biphenyl-4-yl)methyl)-1H-benzamidazole-7-carboxylic acid.,
2-ethoxy-1-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-1,3-benzodiazole-7-carboxylic acid,
2-ethoxy-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-1,3-benzodiazole-7-carboxylic acid,
2-ethoxy-1-<<2'-(1H-tetrazol-5-yl)biphenyl-4-yl>methyl>-1H-benzimidazole-7-carboxylic acid,
2-ethoxy-1-<<2'-(1H-tetrazol-5-yl)biphenyl-4-yl>methyl>-1H-benzimidazole-7-carboxylic acid;,
2-Ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic Acid (Candesartan),
2-ethoxy-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-benzimidazole-7-carboxylic acid,
2-ethoxy-3-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid,
2-Ethoxy-3-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid(CV-11974),
2-Ethoxy-3-[2''-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid,
2-Ethoxy-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid,
Atacand,
Amias,
Candesartan cilexetil,
Blopress (TN),
Ratacand (TN),
Atacand (TN),
Candesartan [INN],
Amias (TN),
D0A0QL,
D0D5SQ,
Candesartan, 98% - 1G 1g,
CID2541,
MFCD00081076,
C24-H20-N6-O3,
ACN-037215,
CS-O-01145,
A5932,
A10175,
Atacand, Blopress, Amias, Ratacand,Candesartan,
C081643,
145040-37-5,
2-ethoxy-1-[4-[2-(1H-tetrazol-5-yl)phenyl]benzyl]-7-benzimidazolecarboxylic acid,
2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4ethyl}-1H-benzimidazole-7-carboxylic acid,
1-((2'-(1H-Tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylic acid,
|
| Complexity | 660 |
| Compound Is Canonicalized | Yes |
| Covalently-Bonded Unit Count | 1 |
| Defined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Exact Mass | 440.16g/mol |
| Formal Charge | 0 |
| Heavy Atom Count | 33 |
| Hydrogen Bond Acceptor Count | 7 |
| Hydrogen Bond Donor Count | 2 |
| Isotope Atom Count | 0 |
| Molecular Weight | 440.463g/mol |
| Monoisotopic Mass | 440.16g/mol |
| Rotatable Bond Count | 7 |
| Topological Polar Surface Area | 119A^2 |
| Undefined Atom Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| XLogP3 | 4.1 |
GHS Hazard and Precautionary Statements
| Symbol: |  |
| Hazard Class | |
| Hazard statements | H302+H312+H332-H315-H319-H335 |
| Packing Group | |
| Precautionary statements | P261-P280-P305+P351+P338 |
| UN Code |
Certificate of Analysis
Lot Number
Related Research Chemicals
CERTIFICATE OF ANALYSIS
| Chemical Name: | Batch Number: | |
| Chemical Structure: | CAS Registry No: | |
| Product ID: | ||
| Manufacture Date: | ||
| Storage Temperature: | ||
| Formula: | ||
| Molecular Weight: | ||
| Quantity: |
Analysis Data:
| Test: | Result: |
Conclusion: The above product meets the specifications of Angene.
Analyst:Chase
Date:
Reviewed by:Jessie
Date:
Angene International Limited